Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Jaundice01:25

Jaundice

35
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
35
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiglycation potential of metal ions and polyphenolic extract of chickpea on thiol-protease inhibitor: A management for diabetic complications.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2024
Same author

Urea induced unfolding of rai seed cystatin: Influence of glycerol as a chemical chaperone.

Colloids and surfaces. B, Biointerfaces·2023
Same author

Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics.

Molecules (Basel, Switzerland)·2022
Same author

Amyloid aggregation and secondary structure changes of liver cystatin: Acidic denaturation and TFE induced studies.

Journal of biomolecular structure & dynamics·2021
Same author

Protein aggregation as a consequence of non-enzymatic glycation: Therapeutic intervention using aspartic acid and arginine.

International journal of biological macromolecules·2020
Same author

Rosmarinic acid restrains protein glycation and aggregation in human serum albumin: Multi spectroscopic and microscopic insight - Possible Therapeutics Targeting Diseases.

International journal of biological macromolecules·2020

Related Experiment Video

Updated: May 1, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K

Bilirubin binding with liver cystatin induced structural and functional changes.

Mir Faisal Mustafa1, Bilqees Bano

  • 1Department of Biochemistry, Faculty of Life Sciences, A.M.U., Aligarh, 202002, UP, India.

Journal of Fluorescence
|April 9, 2014
PubMed
Summary

Bilirubin inactivates liver cystatin by binding to it, altering its structure and function. This interaction may contribute to liver diseases like cirrhosis by disrupting protease-cystatin balance.

More Related Videos

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

16.3K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Related Experiment Videos

Last Updated: May 1, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

16.3K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pathophysiology

Background:

  • Cysteine proteinases and their inhibitors, such as cystatins, are crucial for regulating cellular proteolytic activity.
  • Imbalance between proteases and inhibitors, particularly cathepsins and cystatins, is linked to disease progression.
  • Elevated bilirubin levels, due to conditions like liver fluke infection or bile duct obstruction, can inactivate liver cystatins.

Purpose of the Study:

  • To investigate the interaction between bilirubin (BR) and buffalo liver cystatin (BLC).
  • To explore how bilirubin binding affects cystatin's structure, function, and inactivation.
  • To determine the biophysical and pathophysiological significance of bilirubin-cystatin binding.

Main Methods:

  • UV-absorption spectroscopy
  • Fourier-transform infrared (FT-IR) spectroscopy
  • Fluorescence spectroscopy
  • Caseinolytic activity assay

Main Results:

  • Fluorescence quenching confirmed bilirubin binding to buffalo liver cystatin.
  • Stern-Volmer analysis indicated a static quenching mechanism with approximately one binding site.
  • FT-IR analysis revealed alterations in cystatin's secondary structure and a decrease in its inhibitory activity against papain.
  • Binding constant for the bilirubin-cystatin complex was determined to be 9.279 × 10^4 M⁻¹.

Conclusions:

  • Bilirubin directly binds to and inactivates liver cystatin, causing structural changes.
  • This bilirubin-induced inactivation of cystatin disrupts protease-cystatin balance, potentially contributing to liver cirrhosis.
  • The study highlights the significant biophysical and pathophysiological implications of bilirubin-cystatin interactions in liver health.